From GlobeNewswire: 2024-05-07 08:00:00

Windtree Therapeutics, Inc. has regained compliance with Nasdaq’s minimum bid price requirement after maintaining a closing bid price of $1.00 or more for 10 consecutive trading days. This news comes after Nasdaq’s previous notification of non-compliance due to falling below the minimum bid price. Windtree is a biotechnology company focusing on innovative therapies for critical conditions, such as istaroxime, a Phase II candidate for heart failure. The company also has preclinical candidates for heart failure and oncology. Moving forward, Windtree faces risks and uncertainties related to regulatory approvals, clinical trials, and market acceptance of its products.



Read more at GlobeNewswire: Windtree Therapeutics Regains Compliance with Nasdaq